Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Satoh, Taroh | - |
dc.contributor.author | Kang, Yoon-Koo | - |
dc.contributor.author | Chao, Yee | - |
dc.contributor.author | Ryu, Min-Hee | - |
dc.contributor.author | Kato, Ken | - |
dc.contributor.author | Cheol Chung, Hyun | - |
dc.contributor.author | Chen, Jen-Shi | - |
dc.contributor.author | Muro, Kei | - |
dc.contributor.author | Ki Kang, Won | - |
dc.contributor.author | Yeh, Kun-Huei | - |
dc.contributor.author | Yoshikawa, Takaki | - |
dc.contributor.author | Oh, Sang Cheul | - |
dc.contributor.author | Bai, Li-Yuan | - |
dc.contributor.author | Tamura, Takao | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.contributor.author | Hamamoto, Yasuo | - |
dc.contributor.author | Kim, Jong Gwang | - |
dc.contributor.author | Chin, Keisho | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Minashi, Keiko | - |
dc.contributor.author | Cho, Jae Yong | - |
dc.contributor.author | Tsuda, Masahiro | - |
dc.contributor.author | Tanimoto, Mitsunobu | - |
dc.contributor.author | Chen, Li-Tzong | - |
dc.contributor.author | Boku, Narikazu | - |
dc.date.accessioned | 2021-08-31T15:05:18Z | - |
dc.date.available | 2021-08-31T15:05:18Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2020-01 | - |
dc.identifier.issn | 1436-3291 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/58504 | - |
dc.description.abstract | Background Data on immune checkpoint inhibitor efficacy in patients with human epidermal growth factor receptor 2-positive (HER2+) advanced gastric/gastroesophageal junction (G/GEJ) cancer are lacking. Because HER2 status was not captured in the ATTRACTION-2 trial, we used patients with prior trastuzumab use (Tmab+) as surrogate for HER2 expression status to evaluate the efficacy and safety of nivolumab as third- or later-line therapy in these patients. Methods In ATTRACTION-2, a randomized, double-blind, placebo-controlled, phase 3 multicenter trial, patients were randomized (2:1) to receive nivolumab (3 mg/kg) or placebo every 2 weeks until disease progression or toxicity requiring study discontinuation. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and safety were assessed. Results Of 493 enrolled patients, 81 (nivolumab, n = 59; placebo, n = 22) were Tmab+ and 412 (nivolumab, n = 271; placebo, n = 141) were Tmab-. In both groups, patients receiving nivolumab showed a longer median OS vs placebo (Tmab+, 8.3 [95% confidence interval, 5.3-12.9] vs 3.1 [1.9-5.3] months, hazard ratio, 0.38 [0.22-0.66]; P = 0.0006; Tmab-, 4.8 [4.1-6.0] vs 4.2 [3.6-4.9] months, 0.71 [0.57-0.88]; P = 0.0022). PFS was longer in both groups receiving nivolumab vs placebo (Tmab+, 1.6 [1.5-4.0] vs 1.5 [1.3-2.9] months, 0.49 [0.29-0.85]; P = 0.0111; Tmab-, 1.6 [1.5-2.4] vs 1.5 [1.5-1.5] months, 0.64 [0.51-0.80]; P = 0.0001). Conclusions Nivolumab was efficacious and safe as third- or later-line therapy regardless of prior trastuzumab use in patients with advanced G/GEJ cancer. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | GASTRIC-CANCER | - |
dc.subject | LAPATINIB | - |
dc.subject | PD-L1 | - |
dc.subject | HER2 | - |
dc.title | Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Oh, Sang Cheul | - |
dc.identifier.doi | 10.1007/s10120-019-00970-8 | - |
dc.identifier.scopusid | 2-s2.0-85065787461 | - |
dc.identifier.wosid | 000511763600018 | - |
dc.identifier.bibliographicCitation | GASTRIC CANCER, v.23, no.1, pp.143 - 153 | - |
dc.relation.isPartOf | GASTRIC CANCER | - |
dc.citation.title | GASTRIC CANCER | - |
dc.citation.volume | 23 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 143 | - |
dc.citation.endPage | 153 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | GASTRIC-CANCER | - |
dc.subject.keywordPlus | LAPATINIB | - |
dc.subject.keywordPlus | PD-L1 | - |
dc.subject.keywordPlus | HER2 | - |
dc.subject.keywordAuthor | Nivolumab | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | Gastroesophageal junction cancer | - |
dc.subject.keywordAuthor | Trastuzumab | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.